Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genfit SA
Free Cash Flow
Genfit SA
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Free Cash Flow
-€29.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-7%
|
|
|
Valneva SE
PAR:VLA
|
Free Cash Flow
-€57.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
Inventiva SA
PAR:IVA
|
Free Cash Flow
-€162m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Free Cash Flow
-$121m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-14%
|
|
|
Abivax SA
PAR:ABVX
|
Free Cash Flow
-€154.7m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-26%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Free Cash Flow
€11.3m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Free Cash Flow?
Free Cash Flow
-29.7m
EUR
Based on the financial report for Dec 31, 2025, Genfit SA's Free Cash Flow amounts to -29.7m EUR.
What is Genfit SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-7%
The average annual Free Cash Flow growth rates for Genfit SA have been 26% over the past three years , 21% over the past five years , and -7% over the past ten years .
